NHS National Framework for Transition Products (Nintedanib and Dalbavancin)
Estimated value
—
Awarded value
£14.8m
Suppliers
7
Lots
1
Published
25 Feb 2026
Description
Project title: NHS National Framework for Transition Products (Nintedanib and Dalbavancin) commencing 1st May 2026 Offer reference number: CM/TNS/25/5736 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/25/5736 Nintedanib and Dalbavancin Lot 1 DLN/DNW: 01/05/2026 to 30/09/2027 (17 months) Lot 2 DLS/DNE: 01/05/2026 to 31/05/2027 (13 months) Lot 3 DCE/DSW: 01/05/2026 to 31/01/2027 (9 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Scope
- Reference
- C397096
- Commercial tool
- Standalone contract
- Contract dates
- 30 Apr 2026 to 30 Sept 2027Possible extension to 30 Sept 2029
Option or options to extend (at the discretion of the Authority) up to a maximum of 24 months
- CPV classifications
- 33600000
- Contract locations
- North East England, United KingdomNorth West England, United KingdomEast Midlands, United KingdomWest Midlands, United KingdomEast of England, United KingdomSouth East England, United KingdomSouth West England, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Price is not the only award criterion | Price is not the only award criterion | price | 100.00% |
Submission & procedure
- Procedure
- Open procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£14.8m
Award date
25 Feb 2026
Contract start
30 Apr 2026
Contract end
30 Sept 2027